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AN ECONOMIC EVALUATION OF DROSPIRENONE 2 MG / ESTRADIOL 
1.033 MG VERSUS TIBOLONE 2.5MG IN THE TREATMENT OF 
POSTMENOPAUSAL WOMEN WITH GRADE 1 OR 2 HYPERTENSION IN 
KOREA
Jung S1, Watson PR2, Asukai Y2, Jeong M1
1Bayer Korea, Seoul, South Korea, 2IMS Health, London, UK
OBJECTIVES: The purpose of this study was to assess the cost-effectiveness of dro-
spirenone 2 mg/estradiol 1.033 mg (DRSP/E2) versus tibolone 2.5 mg in the treatment 
of postmenopausal women with Grade 1 or 2 hypertension in Korea. METHODS: A 
lifetime Markov model was developed for a population of postmenopausal women 
indicated for hormone replacement therapy (HRT) who had Grade 1 or 2 hyperten-
sion. Patients initially started on two years of HRT and progressed through the model 
according to their BP status and added on AHT medication as required. Patients 
experienced MI or stroke as determined by their BP status, which is a major risk factor 
for CVD. Continuation rates for HRT and antihypertensive therapy (AHT), CVD risk 
and utilities were obtained from published articles. Unit cost, resource use and treat-
ment practice for AHT were based on physician interviews. Only direct medical costs 
were included. A discount rate of 5% was used for both costs and outcomes according 
to HIRA guidelines. The model reported effectiveness outcomes in quality-adjusted 
life years (QALYs) with a 59% premium price for DRSP/E2 over tibolone. RESULTS: 
DRSP/E2 was cost-effective compared to tibolone. The base case had an incremental 
cost-effectiveness ratio (ICER) of 11,105,517 KRW per QALY gained. Probabilistic 
sensitivity analysis showed 80.4% probability the ICER would fall below the threshold 
of 20 million KRW. BP lowering qualities of DRSP/E2 provide additional beneﬁts of 
decreased need for AHT medication and decreased risk of myocardial infarction (MI) 
and stroke for postmenopausal women with Grade 1 or 2 hypertension. CONCLU-
SIONS: In Korea, DRSP/E2 proved cost-effectiveness compared to tibolone offering 
additional beneﬁt of aiding BP control compared to standard HRT.
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ECONOMIC EVALUATION OF TWO ALTERNATIVE TREATMENTS FOR 
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OBJECTIVES: To compare the cost-effectiveness of traditional treatment for ovarian 
stimulation in assisted reproduction techniques (ART) based on a combination of 
agonists of the Gonadotrophin released hormone (GnRH) versus a treatment based 
on the use of antagonist of the GnRH. METHODS: Cost-effectiveness analysis where 
both, effectiveness and costs are estimated by means of a clinical study carried out in 
the University Hospital Virgen de las Nieves of Granada (Spain) including patients in 
their ﬁrst cycle. Effectiveness was measured as the number of ongoing pregnancies 
reached with each treatment. Direct costs were considered, for hospital and for 
patients as well. Markov model was used to simulate the clinical path of the compared 
techniques. Deterministic and probabilistic sensitivity analyses were used to analyse 
preliminary results. RESULTS: The clinical study included 274 patients, 138 treated 
with agonists and 136 with antagonists. No statistically signiﬁcant differences were 
founded regarding age, cause of infertility and insemination technique used. Deter-
ministic analysis showed the agonists’ treatment to be more effective than antagonists’ 
(33/138 versus 20/136 pregnancies respectively) but more costly (mean cost a3,204.37 
versus a3,066.64a), with an incremental cost effectiveness ratio (ICER) of a14.96. 
Deterministic sensitivity analysis shows high sensitivity of ICER to effectiveness but 
not to cost of treatments. On the other hand, probabilistic analysis shows the agonist 
treatment to be a dominant strategy versus antagonist treatment. CONCLUSIONS: 
The use of antagonists of GnRH for ovarian stimulation in ART has been broadly 
discussed, but no cost-effectiveness studies have been carried out. Both, deterministic 
and probabilistic analyses show that, for women in the ﬁrst cycle of ART, agonist 
treatment reports the best cost-effectiveness ratio in comparison with antagonist treat-
ment. However, while the results of deterministic analysis are very sensitive to varia-
tions in treatment effectiveness, probabilistic analysis’ results reveal a robust dominance 
of agonists treatment.
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OBJECTIVES: To evaluate the cost effectiveness of Evra in Mexico from the Popular 
Healthcare System (PHcS) perspective, that is the recently public third-party payer 
created for self-employed workers and low-income families outside the social security 
system. METHODS: We developed a Markov model to assess costs and beneﬁts 
associated with the use of Evra in 5-yearly age groups Mexican women. Number of 
pregnancies averted per 100 users was the effectiveness outcome, which was derived 
from expert panel estimates based on pregnancy probabilities for hormonal contracep-
tive methods taken from the 2006 National Demography Survey and one international 
paper. Contraceptive methods cost and pregnancy costs were included in the model 
at 2009 values. Comparators for Evra were oral contraceptives (OC’s) and monthly 
injections, although injections only were compared for ages 30–44. A three-year time 
horizon was used for base-case analysis, but one-way sensitivity analyses was per-
formed to vary the intergenesic interval from one year to ﬁve years, using a 5% dis-
count rate. Probabilistic sensitivity analyses were undertaken to incorporate likely 
distributional properties of key model parameters RESULTS: According to base-case 
analysis Evra appear as the dominant strategy compared against OC’s. The largest 
cost-savings (a20,700) were obtained for ages 25–29 where 37 additional pregnancies 
were prevented, being pregnancy the main cost driver. Comparison between Evra 
and monthly injections produced ICER estimates in a range from a667 to a2943 per 
pregnancy averted for 40–44 and 30–34 age-groups respectively. Sensitivity analysis 
results showed robustness of model parameters. CONCLUSIONS: Compared with 
OC’s, Evra represents a more effective and less costly contraceptive method for 
Mexican women covered by PHcS, while compared with injections, Evra is a highly 
cost-effective option.
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OBJECTIVES: To perform a pharmacoeconomic evaluation of Evra in Mexico from 
the perspective of insurance companies METHODS: We used a Markov analytical 
model to assess costs and beneﬁts associated with the use of Evra in quinquennial 
age-groups Mexican women covered by a private health insurance. Comparator for 
Evra was oral contraceptives (OC’s). Effectiveness measure was the number of preg-
nancies averted per 100 users. These values were estimated by expert panel consensus 
based on pregnancy probabilities for hormonal contraceptive methods taken from the 
2006 National Demography Survey and literature review. Contraceptive methods 
costs were calculated using the market prices, while mean values of medical reimburse-
ment tabulator were used as proxy of pregnancy costs and adjusted to 2009 values. 
We assumed a 3-years intergenesic interval for base-case evaluation; however through 
one-way sensitivity analyses we knew the impact of varying the intergenesic interval 
from one year to ﬁve years, using a 5% discount rate. Probabilistic sensitivity analyses 
via Monte Carlo simulations were undertaken to incorporate likely distributional 
properties of key model parameters. RESULTS: Base-case results showed Evra as the 
dominant strategy, obtaining savings in a range of a4840 for ages 30–34 until a7454 
for ages 25–29, being contraceptive method the main cost driver for both options. 
Also Evra enable to prevent between 10 and 14 additional pregnancies compared 
against OC’s. From one-way sensitivity analysis cost-savings exhibited a growing 
pattern until year 3, and a decreasing trend towards year 5. These results were con-
sistent for all cohorts, however certain differences were observed between 15–19 and 
25–29 age-groups at year 1. CONCLUSIONS: Compared with OC’s, Evra represents 
a more effective and less costly contraceptive method for Mexican women.
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OBJECTIVES: This study was conducted to evaluate the cost-effectiveness of recom-
binant FSH (rFSH) and LH (rLH) for treatment in vitro fertilization (IVF) patients 
from the payer’s perspective. METHODS: A cost-effectiveness analysis from retrospec-
tive database of women waiting to be come pregnant (1100 IVF cycles). All patients 
received rFSH in combination with rLH or HP-hMG or non-puriﬁed hMG. Based on 
ovarian reserve, initial dose varied from 150 to 450 IU of r-hFSH associated with 75 
to 225 IU of rLH or 1 to 4 vials of hMG. Statistical analysis was performed using the 
SPSS. In addition, a probabilistic sensitivity analysis was conducted by Boostrap simu-
lation. RESULTS: Clinical and ongoing pregnancy rates (PR) per cycle were: rLH 
47.16% and 44.95%; hMG 37.86% and 37.0%; HP-hMG 31.77% and 28.13%. 
PR with rFshrLH were signiﬁcantly higher than with urinary products (P  0.05), 
however mean age was signiﬁcantly lower (rLH 35.27 o 4.30; hMG 35.94 o 4.69; 
HP-hMG 36.25 o 4.64; P  0.05). Patient age group analysis showed than 35 years 
had higher PR in the rFSHrLH group compared to rFSHHP-hMG (clinical PR: 
57.47% vs 32.76%, P  0.01; ongoing PR 54.71% vs 27.59%, P  0.01). The non 
puriﬁed hMGrFSH group had lower PR than the rFSHrLH group (clinical PR: 
46.71% and 57.47%, P  0.05), but the difference in ongoing PR did not reach sta-
tistical signiﬁcance (46.11% and 54.71%,). Costs of gonadotropins in patients 35 
years were: non-puriﬁed hMG (6616.74 o a1100.97)  rLH (6819.71 o a1204.30 or 
7064.91 o a1246.28 using the unit costs of combo of rFSH 150 IU  rLH 75 IU and 
free combination respectively)  HP-hMG 7103.36 o a1121.89. It was therefore 
showed rFSH 150 UI rLH 75 UI combination is more effective than rFSHHP-hMG. 
CONCLUSIONS: This study indicate that rFSH 150 UI rLH 75 UI treatment is a 
dominant option, lower costs and higher effectiveness, with respect to HP-hMG and 
free combination. rFSHrLH is the most cost-effectiveness option.
